Member Info for K3VMC

Very, very lovely.

Morning Bob. What price apt now, please?

Well, �20.2k of that is my buy. I care neither a jot nor a tittle, who is selling, or why. I am getting them cheaper than last month, so wot me worry. I may have to pay more next week, or maybe less, but I will still be buying. This will be a multi bagger next year. 0.5p 0.6p. Who cares?

I can sell 7m@0.488 and 9m@0.48.

My trade will be late reported at 0.505p. Must stop now!!

Mr Masterman on vox markets uses the 270,000 mtu figure at the current spot price!! $50-60m sales in 2019. Please pass that on to jaf1948. Happy days.

TPI has produced a very detailed research note on WRES. I picked up a hard copy of it at their latest investor evening, when Mr Masterman gave his excellent, updated presentation. I strongly suggest that investors get in touch with them, as per contact details on any RNS, and ask them to email a copy.

L200, I believe that Ormonde is producing exactly the same amount of WO3 as WRES is. WRES plans to ramp up production over time and the multiple assets we own should dwarf The Ormonde mine, within a year or two. Also worth noting that WRES owns 100% of its assets. Ormonde has 20%? 25%? Regardless of size and ownership differences, I wish you great success with your investment and I am happy that you are creating jobs and wealth in the region. ATB

Bob, at least you got a picture of Regua now!

Very good to meet you too. We hope to see you on the LP trip, if not before.

Bob, I'm on the phone to him now!!

Justine James will provide a sling for said posterior. My suggestion is that we go BA to Seville and ask the LP guys to send a limo. First time, I went to Madrid with the missus for a week, but left her there for a couple of days and went to LP in a hired car. In February, we went to Seville for a week and took the bus up to Merida. Just over two hours and they have free wifi on the bus. No way was I going to get in a car after a few days of Rioja Crianza. Menu of the day is �10 in the plaza major, although we ate in more refined establishments (obviously). Joking, of course, but the food there is lovely and the LP guys are fantastic hosts and great company. Not to be missed.

But I have to admit, I have never seen Tonnacombe and RR in the same room.

Sorry Bob, nameless refers to my esteemed fellow investor who got his limit order ahead of mine. RR was just a buying signal for me. He referred to jaf1948 as being one of the more astute posters on here, even though jaf used higher finance costs and lower tungsten price and production amounts. Desperate stuff. All good here. Foundations being poured, steel ordered, equipment arriving soon and a site visit in September. Now, there would be no point organising an investor site visit, if there were no sights to see, would there? I predict a very swift erection. I hand the microphone back to Bob.

RR obviously knew something was going on today, which was why he appeared. It kind of back-fired though. We all know the sp tends to move up shortly after he materialises. I was planning to buy more over the next week or so, but brought that forward. Looks like some other investors had the same idea. Sadly, one of mine had to be at 0.505p as I was competing with someone who shall remain nameless!!

Nolupus, there you go again! I did not say that Benlysta had caused ANY deaths, as you well know. Look at the side effects listed on the Benlysta site. Cancer. BENLYSTA may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers. Allergic (hypersensitivity) reactions. Serious allergic reactions can happen on the day of, or in the days after, receiving BENLYSTA and may cause death. So, there is no point in asking a disingenuous question about numbers of deaths. Complete v full? You take care of semantics as you wish. I am more straight forward than that / I am not interested in splitting hairs. You think that Lupuzor failed badly. That is your value judgement. I prefer the scientific approach. It worked better than the placebo, but not at the statistical level required by the trial. That is a well-documented fact, which I cannot change and do not dispute. My view is that there is enough merit in the treatment, given its efficacy and safety profile, that may, with the benefit of data gathered on the further effects on the health of all patients in the extended trial, give enough encouragement to the FDA to allow the treatment to go into production. That view will be tested during the next few months. Remember that the data will be available at four week intervals. It is an open trial and the data can be shared with big pharma and the FDA as IMM sees fit. Lots to look forward to here, for us those of us invested in IMM.

Bob, there is certainly something going on below the surface, as you would expect when RR turns up. You will find at least another 7m late trades being reported. All buys.

IF IMM can show that the patients in the extended trial improved their symptoms and, hopefully, another 7-8% have gone into complete remission, that will be an extremely strong argument for getting Lupuzor over the FDA try line. The FDA would have a hard job in holding that back, especially if the more granular analysis of p3 trial data gives additional support to gaining approval. We are talking about an unmet medical need to reduce the considerable suffering of 5m people worldwide, not a more effective headache pill. Lupuzor can provide COMPLETE remission, with NO SERIOUS SIDEFFECTS. The FDA will not, IMHO, let a marginal failure to achieve statistical significance, on a relatively small patient population, stand against the desire of clinicians and patients to give them a decent chance of reducing their pain and suffering. All IMHO, DYOR!!

Shorting algobots. Shorters will have to close at some point. Algobots will keep on dribbling in trades, waiting for humans investors to get bored, worried, restless and give up. Patience is a virtue. I will happily drip feed buys here until the shorters give up and go for richer pickings.

There is often more than one reason for taking a course of action. The good reason and the real reason. Yes, this is nominally a safety and tolerability extension test (good reason), but what you conveniently forgot to mention is the secondary target (and in my view real reason). Secondary Outcome Measures : the effect in the Clinical SLEDAI-2K total score by at final visit compared to initial visit [ Time Frame: at week 28 ] The SLEDAI 2K is a validated objective measure that assesses disease activity within the last 28 days before completion of the index. It is a global index and includes 24 weighted clinical and laboratory variables. The SLEDAI-2K clinical score is the calculated score without inclusion of the points that may be contributed by having a psoitive titer fr anti-dsdna Ab or decreased serum complement level. The SLEDAI-2K clinical score (sum of 22 scores) ranges from 0 to 101. Remission of the disease (i.e reduction of clinical SLEDAI-2K score to 0) [ Time Frame: at week 28 ] Inclusion of that target makes a whole lot of difference to the slant you put on it.